Long‐term treatment of benign prostatic hyperplasia with alfuzosin: a 24–30 month survey

Abstract

These data demonstrate the usefulness of long-term treatment with alfuzosin in patients with uncomplicated, moderate BPH.

Clinical Uroselectivity of Alfuzosin in the Treatment of Benign Prostatic Hyperplasia

“…Urinary flow rates also improved with peak flow rate increasing from 13.6 ml/s at baseline to 14.6 ml/s after 18 months [11]. Long-term maintenance of symptomatic improvement up to 30 months was demonstrated in a further open extension of this study involving 50 patients [12] (fig. 1).…”

“…Of 122 patients completing 12 months therapy, all obstructive and irritative symptoms were improved; the Boyarsky score decreased from 8.7 ± 0.3 at baseline to 5.2 ± 0.3 at 24 months [12]. Urinary flow rates also improved with peak flow rate increasing from 13.6 ml/s at baseline to 14.6 ml/s after 18 months [11].…”

Alpha–1–adrenoceptor blockade in the treatment of benign prostatic hyperplasia

“…62 Alfuzosin has been shown to improve Boyarsky symptom scores 40% (3.5 units) from baseline (8.7 units) for up to 24 months (n 50) and¯ow rates 7% (1.0 mLas) from baseline (13.6 mLas) for up to 12 months (n 46); alfuzosin, however, failed to maintain improvements in¯ow at 24 months (n 20), when¯ow rates decreased À6% (À0.9 mLas) from baseline (15.0 mLas). 4 Despite these studies, the long-term durability of these agents is still unknown and uncertain. It should be noted that the results of open-label studies may be somewhat enhanced because responding patients are included in the results and those withdrawing are not.…”

“…In a 24 ± 30-month study of alfuzosin, the side effects with the highest incidence were dizziness, headache, and malaisea postural hypotension. 4 …”

Tamsulosin Versus Terazosin for Benign Prostatic Hyperplasia: A Systematic Review

“…The preference has been for longer acting and more uroselective a 1 -adrenoceptor antagonists [Brawer et al 1993]. Prazosin [Roehrborn et al 1995], terazosin [Chapple et al 1994], doxazosin [Jardin et al 1994], and alfuzosin [Kunisawa et al 1985], a 1 -adrenoreceptor antagonists have been used to treat BPH and increase urinary outflow and lessen symptoms. However, their use is associated with adverse effects that included dizziness, severe hypotension and dry mouth.…”